NASDAQ
GLTO

Galecto Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Galecto Inc Stock Price

Vitals

Today's Low:
$0.5632
Today's High:
$0.669
Open Price:
$0.5632
52W Low:
$0.545
52W High:
$3.7
Prev. Close:
$0.57
Volume:
1145208

Company Statistics

Market Cap.:
$16.13 million
Book Value:
1.617
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-42.69%
Return on Equity TTM:
-80.05%

Company Profile

Galecto Inc had its IPO on 2020-10-29 under the ticker symbol GLTO.

The company operates in the Healthcare sector and Biotechnology industry. Galecto Inc has a staff strength of 45 employees.

Stock update

Shares of Galecto Inc opened at $0.56 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.56 - $0.67, and closed at $0.64.

This is a +12.28% increase from the previous day's closing price.

A total volume of 1,145,208 shares were traded at the close of the day’s session.

In the last one week, shares of Galecto Inc have increased by +8.47%.

Galecto Inc's Key Ratios

Galecto Inc has a market cap of $16.13 million, indicating a price to book ratio of 0.5276 and a price to sales ratio of 0.

In the last 12-months Galecto Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-51736000. The EBITDA ratio measures Galecto Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Galecto Inc’s operating margin was 0% while its return on assets stood at -42.69% with a return of equity of -80.05%.

In Q2, Galecto Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Galecto Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Galecto Inc’s profitability.

Galecto Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.4917. Its price to sales ratio in the trailing 12-months stood at 0.

Galecto Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$58.80 million
Total Liabilities
$14.90 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Galecto Inc ended 2024 with $58.80 million in total assets and $0 in total liabilities. Its intangible assets were valued at $58.80 million while shareholder equity stood at $43.70 million.

Galecto Inc ended 2024 with $0 in deferred long-term liabilities, $14.90 million in other current liabilities, in common stock, $-241474000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $22.96 million and cash and short-term investments were $52.12 million. The company’s total short-term debt was $420,000 while long-term debt stood at $0.

Galecto Inc’s total current assets stands at $55.36 million while long-term investments were $0.00 and short-term investments were $29.17 million. Its net receivables were $1.19 million compared to accounts payable of $5.56 million and inventory worth $1.89 million.

In 2024, Galecto Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Galecto Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.64
52-Week High
$3.7
52-Week Low
$0.545
Analyst Target Price
$4.75

Galecto Inc stock is currently trading at $0.64 per share. It touched a 52-week high of $3.7 and a 52-week low of $3.7. Analysts tracking the stock have a 12-month average target price of $4.75.

Its 50-day moving average was $1.82 and 200-day moving average was $1.96 The short ratio stood at 0.47 indicating a short percent outstanding of 0%.

Around 445.1% of the company’s stock are held by insiders while 3913.3% are held by institutions.

Frequently Asked Questions About Galecto Inc

The stock symbol (also called stock or share ticker) of Galecto Inc is GLTO

The IPO of Galecto Inc took place on 2020-10-29

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$81
-4.26
-5%
$1.92
0.01
+0.52%
$11.5
0.25
+2.22%
Nelcast Limited (NELCAST)
$129.15
-8
-5.83%
$41.29
-1.07
-2.53%
$57.25
-0.96
-1.65%
$459.7
-1.1
-0.24%
$17.03
0
0%
$18.3
0.14
+0.77%
$67.49
-0.5
-0.74%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company’s lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Address

75 State Street, Boston, MA, United States, 02109